Short answer: This article explains the key facts, eligibility issues, settlement factors, deadlines, and source-backed updates related to this legal topic. Results vary by case facts, evidence, jurisdiction, and representation.
Depo-Provera Daubert Hearing 2026: June 24 Date, 6,000 Cases and What It Means
The Depo-Provera Daubert hearing scheduled for June 24–26, 2026 is a pivotal Rule 702 hearing in the federal meningioma litigation against Pfizer and related defendants.
With roughly 6,000 filed or reported claims tied to Depo-Provera and generic depot medroxyprogesterone acetate, the Depo-Provera Daubert hearing may determine whether key causation experts can testify before juries.
Quick Answer: Why the Depo-Provera Daubert Hearing Matters
The Depo-Provera Daubert hearing is important because it tests whether plaintiffs’ scientific experts may tell a jury that Depo-Provera or generic depot medroxyprogesterone acetate can cause intracranial meningioma. The Northern District of Florida’s MDL page lists the litigation as MDL No. 3140 and describes allegations that injectable contraceptive Depo-Provera or generic equivalents can cause users to develop one or more meningiomas.
- Hearing date: June 24–26, 2026 Rule 702 motions hearing.
- Court: U.S. District Court, Northern District of Florida.
- Judge: M. Casey Rodgers.
- Core issue: Whether expert causation testimony is admissible.
- Reported case volume: Roughly 6,000 filed or reported claims, depending on the tracker used.
- Potential next step: Bellwether trials and stronger settlement negotiations if plaintiffs clear the expert-evidence hurdle.
What Is the Depo-Provera Daubert Hearing?
A Daubert hearing is a pretrial proceeding where a judge decides whether proposed expert testimony is reliable and relevant enough for trial. In this litigation, the Depo-Provera Daubert hearing focuses on scientific opinions about whether medroxyprogesterone acetate, the active progestin in Depo-Provera, can cause meningioma.
The court’s MDL page states that transferred actions share allegations that injectable contraceptive Depo-Provera or its generic equivalents can cause users to develop meningiomas, while defendants maintain the medication is safe and effective. That dispute is why the Depo-Provera Daubert hearing is now the central event in the litigation.
The official hearing-date page for MDL No. 3140 lists a Rule 702 motions hearing for June 24–26, 2026. Rule 702 is the federal evidence rule that governs expert testimony, so the Depo-Provera Daubert hearing is where the judge evaluates the methods, data, and reasoning behind the plaintiffs’ causation experts.
Why the Depo-Provera Daubert Hearing Could Shape the Entire Lawsuit
The Depo-Provera Daubert hearing does not decide every plaintiff’s case. It does, however, decide whether the key scientific opinions can be used in future trials. In a pharmaceutical mass tort, that expert-evidence ruling can change settlement pressure, trial leverage, and the speed of negotiations.
If Plaintiffs Win
Admissible expert testimony may allow bellwether trials to proceed and may increase pressure on defendants to discuss broader settlement terms.
If Defendants Win
An exclusion ruling could weaken plaintiffs’ ability to prove causation and may reduce settlement leverage unless the ruling is narrowed, reconsidered, or appealed.
If the Ruling Is Mixed
The court may allow some experts or opinions while limiting others. A mixed Depo-Provera Daubert hearing result can still move selected claims forward.
Because the litigation centers on meningioma risk, expert testimony on epidemiology, biological plausibility, dose-response evidence, medical causation, and warnings is likely to be central. The Depo-Provera Daubert hearing is therefore more than a scheduling event; it is a gatekeeping test for the science that could reach juries.
Depo-Provera Lawsuit 6,000 Cases: What the Number Means
References to “6,000 cases” should be read carefully. Different sources may count filed federal MDL cases, state-court cases, registered claims, tolling-agreement claims, or attorney-reported inventories differently. For SEO and reader accuracy, this article describes the Depo-Provera Daubert hearing against a backdrop of roughly 6,000 filed or reported claims rather than claiming one single verified federal docket number.
The official court page confirms MDL No. 3140 and the nature of the coordinated allegations. Case-count trackers and law-firm updates have reported rapid growth through 2026, but official docket counts may lag behind intake numbers. The safest wording is that the Depo-Provera Daubert hearing arrives as the litigation has become one of the larger and fastest-growing pharmaceutical mass torts of 2026.
How the Depo-Provera Daubert Hearing Could Affect Settlement Amounts
No global Depo-Provera settlement has been announced. The Depo-Provera Daubert hearing may still affect settlement values because expert admissibility often influences whether defendants face trial risk. If the court allows plaintiffs’ causation experts, settlement pressure may rise before bellwether trials.
| Possible Outcome | Likely Litigation Effect | Settlement Impact |
|---|---|---|
| Plaintiffs’ experts admitted | Claims move closer to bellwether trials. | May increase settlement leverage and accelerate negotiations. |
| Some opinions limited | Selected claims or expert theories may survive. | May create tiered negotiations based on evidence strength. |
| Major causation opinions excluded | Plaintiffs may face a much harder path at trial. | May reduce settlement pressure unless appealed or narrowed. |
Published settlement ranges for Depo-Provera meningioma lawsuits remain speculative. Claims involving surgical removal, permanent neurological problems, vision impairment, cognitive harm, lost income, and strong injection records may be valued differently from claims involving watchful waiting or less severe harm. The Depo-Provera Daubert hearing will not assign individual values, but it may influence the negotiation environment.
To compare claim value factors, use the TortAdvisor settlement calculator hub or review the Depo-Provera settlement amounts guide.
Who May Qualify for a Depo-Provera Meningioma Lawsuit?
The Depo-Provera Daubert hearing is not limited to one plaintiff’s story, but individual eligibility still depends on medical and prescription facts. Attorneys commonly review claims involving Depo-Provera or generic depot medroxyprogesterone acetate injections followed by an intracranial meningioma diagnosis.
Injection History
Records showing repeated Depo-Provera or generic medroxyprogesterone acetate injections may support exposure and dose history.
Meningioma Diagnosis
MRI, CT, pathology, neurosurgery, radiation, or monitoring records can document the injury and treatment course.
Filing Deadline
State statutes of limitation vary. Diagnosis date, discovery date, and state law can affect whether a claim can still be filed.
People who never had surgery may still request a legal review if they have a confirmed meningioma diagnosis and documented exposure. The Depo-Provera Daubert hearing may affect overall litigation leverage, but it does not replace a claim-specific statute-of-limitations review.
Depo-Provera Lawsuit Timeline After the June 24 Hearing
The Depo-Provera Daubert hearing is scheduled for June 24–26, 2026, but the ruling may come later. After argument, the court may issue a written order addressing which experts and opinions are admissible.
- June 24–26, 2026: Rule 702 motions hearing in MDL No. 3140.
- Post-hearing order: Judge Rodgers rules on expert admissibility.
- Bellwether preparation: If claims proceed, selected cases move toward trial preparation.
- Settlement pressure: A favorable ruling for plaintiffs may increase negotiation pressure before trial.
- Claim review: New claimants should confirm injection records, diagnosis records, and deadlines as soon as possible.
The Depo-Provera Daubert hearing is therefore a catalyst, not the final chapter. It may determine whether the litigation moves into bellwether trials with stronger causation evidence, but final compensation still depends on individual proof and broader settlement negotiations.
Depo-Provera Daubert Hearing FAQ
When is the Depo-Provera Daubert hearing?
The Depo-Provera Daubert hearing is scheduled for June 24–26, 2026 as a Rule 702 motions hearing in MDL No. 3140.
What will the judge decide at the Depo-Provera Daubert hearing?
The judge will decide whether expert opinions about the relationship between Depo-Provera, depot medroxyprogesterone acetate, and meningioma are reliable and admissible for trial.
Does the Depo-Provera Daubert hearing guarantee a settlement?
No. The Depo-Provera Daubert hearing may influence settlement leverage, but it does not guarantee a payout or a specific settlement amount.
What if I used generic Depo-Provera?
The MDL describes allegations involving Depo-Provera or generic equivalents. Generic-use claims should be reviewed by an attorney because product identification, warnings, and state law can affect the analysis.
Should I wait for the Depo-Provera Daubert hearing before filing?
Waiting can be risky because filing deadlines vary by state. Anyone with a meningioma diagnosis after Depo-Provera use should request a deadline review now.
Sources and Citations
The following sources support the court schedule, MDL background, labeling language, and medical-science context discussed in this article.
- U.S. District Court, Northern District of Florida — Depo-Provera Products Liability Litigation, MDL No. 3140
- U.S. District Court, Northern District of Florida — Important Hearing Dates and Rule 702 Motions Hearing
- U.S. District Court, Northern District of Florida — MDL No. 3140 Orders by Date
- FDA Prescribing Information — Depo-Provera / Medroxyprogesterone Acetate Meningioma Warning
- PubMed — Depot Medroxyprogesterone Acetate and Risk of Meningioma
- FDA — Progestin-Containing Products and Meningioma Labeling Update
Were You Diagnosed With Meningioma After Depo-Provera?
The Depo-Provera Daubert hearing may affect the litigation, but filing deadlines can still control your individual rights. Get a confidential review of your injection history, diagnosis, records, and deadline.
Related Posts
Get expert help from Mesa Arizona car accident lawyers to protect your rights and maximize your settlement after a crash.
Find top accident lawyers in Miami FL for max compensation after crashes. Expert guidance on claims, settlements & Miami laws. Call now!
